ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Intergroup 5-FU/Levamisole Study Positive Enough Now To End Untreated Control Arms

September 22, 1989

DCCP To Have Board Of Scientific Counselors

September 1, 1978

DCPC Forms Decision Network To oversee Chemoprevention

July 16, 1993

DCCPT Board, NCAB Approve Core Grant Guideline Changes, Consortium Centers

May 17, 1985

Kimmel Donates $150 Million To Hopkins For Cancer Research, Patient Residence.

November 16, 2001

RPR Grant To NABCO Does Not Support Advocacy, Firm Says

November 10, 1995